Brookline Capital Markets Starts Opus Genetics (IRD) at Buy

December 1, 2025 8:46 AM EST Send to a Friend
Brookline Capital Markets analyst Kumaraguru Raja initiates coverage on Opus Genetics (NASDAQ: IRD) with a Buy rating and a price ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login